Acute Megakaryoblastic Leukemia
Welcome,         Profile    Billing    Logout  
 38 Companies   60 Products   60 Products   52 Mechanisms of Action   1 Trial   233 News 


12345»
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
    Phase classification, Enrollment change, Trial termination:  Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia (clinicaltrials.gov) -  Aug 23, 2018   
    P1,  N=7, Terminated, 
    Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017 Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply
  • ||||||||||  peripheral blood stem cell transplantation / National Cancer Institute
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) -  Mar 31, 2018   
    P1,  N=10, Terminated, 
    N=30 --> 17 | Recruiting --> Terminated; Accrual factor N=35 --> 10 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Jul 2017; Insufficient Accrual
  • ||||||||||  mitoxantrone / Generic mfg., gemcitabine / Generic mfg.
    Trial termination:  Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 22, 2018   
    P2,  N=24, Terminated, 
    Completed --> Terminated; If </= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients (21%) of 24 enrolled patients had a CR so the study was terminated.
  • ||||||||||  Biomarker, Trial completion, Trial initiation date, Trial primary completion date:  Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  May 17, 2017   
    P=N/A,  N=30, Completed, 
    Not yet recruiting --> Completed Not yet recruiting --> Completed | Initiation date: Sep 2010 --> May 2009 | Trial primary completion date: Oct 2010 --> Jun 2009
  • ||||||||||  Trial completion, Trial primary completion date:  Study of Bone Marrow Samples From Patients With Acute Leukemia (clinicaltrials.gov) -  May 17, 2017   
    P=N/A,  N=40, Completed, 
    Not yet recruiting --> Completed | Initiation date: Oct 2009 --> Jul 2010 | Trial primary completion date: Nov 2009 --> Aug 2010 Active, not recruiting --> Completed | Trial primary completion date: Aug 2099 --> Nov 2009
  • ||||||||||  metformin / Generic mfg., cytarabine / Generic mfg.
    Trial primary completion date:  Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (clinicaltrials.gov) -  Sep 2, 2016   
    P1,  N=2, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Jul 2018
  • ||||||||||  Biomarker, Trial completion, Trial primary completion date:  Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  May 19, 2016   
    P=N/A,  N=234, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
  • ||||||||||  Trial completion, Trial primary completion date:  Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia (clinicaltrials.gov) -  May 19, 2016   
    P=N/A,  N=100, Completed, 
    Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
  • ||||||||||  metformin / Generic mfg., cytarabine / Generic mfg.
    Enrollment closed, Enrollment change:  Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (clinicaltrials.gov) -  Feb 24, 2016   
    P1,  N=2, Active, not recruiting, 
    Trial primary completion date: Feb 2016 --> Jul 2017 Recruiting --> Active, not recruiting | N=28 --> 2
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Enrollment change, Trial termination, Trial primary completion date:  Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 26, 2016   
    P2,  N=4, Terminated, 
    Recruiting --> Active, not recruiting | N=28 --> 2 N=16 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Nov 2015; Regulatory
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Clinical:  Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) -  Dec 21, 2015   
    P2,  N=14, Completed, 
    Recruiting --> Completed | N=200 --> 263 | Trial primary completion date: Dec 2013 --> Jul 2015 Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015
  • ||||||||||  cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date, Combination therapy:  Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Dec 16, 2015   
    P2,  N=134, Completed, 
    Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015 Active, not recruiting --> Completed | N=195 --> 134 | Trial primary completion date: Sep 2016 --> Dec 2015